Haemonetics (NYSE:HAE) Given Buy Rating at Needham & Company LLC

Haemonetics (NYSE:HAE - Get Free Report)'s stock had its "buy" rating restated by analysts at Needham & Company LLC in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $112.00 price target on the medical instruments supplier's stock. Needham & Company LLC's target price points to a potential upside of 25.53% from the company's previous close.

A number of other research analysts also recently issued reports on the company. JMP Securities reiterated a "market outperform" rating and set a $125.00 price objective on shares of Haemonetics in a report on Tuesday, August 13th. Barrington Research reaffirmed an "outperform" rating and set a $108.00 price target on shares of Haemonetics in a research note on Friday, November 8th. Raymond James raised shares of Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 price objective on the stock in a research report on Friday, November 8th. CL King started coverage on shares of Haemonetics in a research report on Friday, September 13th. They issued a "buy" rating and a $116.00 target price for the company. Finally, Citigroup reduced their price objective on shares of Haemonetics from $94.00 to $85.00 and set a "neutral" rating for the company in a research note on Thursday, August 22nd. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $107.88.

Haemonetics Trading Down 1.7 %

NYSE:HAE traded down $1.53 during trading hours on Friday, hitting $89.22. The stock had a trading volume of 564,401 shares, compared to its average volume of 555,780. The business's 50 day moving average is $77.55 and its 200-day moving average is $82.75. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. The company has a market cap of $4.48 billion, a price-to-earnings ratio of 37.02, a P/E/G ratio of 1.43 and a beta of 0.32. Haemonetics has a one year low of $70.25 and a one year high of $97.97.

Haemonetics (NYSE:HAE - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, beating analysts' consensus estimates of $1.09 by $0.03. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The business had revenue of $345.50 million during the quarter, compared to analysts' expectations of $342.57 million. During the same quarter in the prior year, the company earned $0.99 EPS. The firm's quarterly revenue was up 8.6% on a year-over-year basis. Sell-side analysts anticipate that Haemonetics will post 4.59 EPS for the current fiscal year.

Institutional Trading of Haemonetics

A number of hedge funds have recently made changes to their positions in HAE. Geode Capital Management LLC raised its position in shares of Haemonetics by 1.8% in the third quarter. Geode Capital Management LLC now owns 1,193,927 shares of the medical instruments supplier's stock valued at $95,986,000 after purchasing an additional 21,547 shares during the period. Y Intercept Hong Kong Ltd acquired a new stake in Haemonetics during the third quarter worth approximately $382,000. XTX Topco Ltd boosted its holdings in shares of Haemonetics by 84.9% during the third quarter. XTX Topco Ltd now owns 8,450 shares of the medical instruments supplier's stock worth $679,000 after acquiring an additional 3,880 shares during the period. Zacks Investment Management grew its position in shares of Haemonetics by 11.5% in the third quarter. Zacks Investment Management now owns 16,921 shares of the medical instruments supplier's stock valued at $1,360,000 after purchasing an additional 1,740 shares during the last quarter. Finally, iSAM Funds UK Ltd bought a new position in shares of Haemonetics during the third quarter worth approximately $204,000. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.